Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Abstract In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Haiyan Chen, Isabel Reeder, Lindsay N. Carpp, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Thomas Jones, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, On behalf of the United States Government (USG) COVID-19 Immune Assays Team, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-09-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-024-52348-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!